Pulse.

a daily field guide to health research that matters

◆ Console

‹ Tue · 3 Nov 2026
Promising but preliminary

Dapagliflozin attenuates progression from prefrailty to frailty in patients with hypertension and chronic kidney disease.

A kidney disease medication reduced older adults' risk of becoming frail by nearly 87%, suggesting physical decline isn't inevitable.

BACKGROUNDChronic kidney disease (CKD) and hypertension share common pathophysiological pathways contributing to vascular damage, endothelial dysfunction, and physical decline, particularly in older adults with prefrailty. In adjusted analyses, receiving dapagliflozin was independently associated with lower odds of progressing to frailty at 1 year (OR = 0,130, CI 0,045-0,381, P < 0,001),CONCLUSIONIn older hypertensive patients with CKD, greater renal injury is associated with worse physical performance, while dapagliflozin use reduces the risk of frailty progression.

What the study was

Study design
Clinical cohort study
Population
older adults
Category
Prevention
Maturity
Validated
Journal
The Journal of clinical investigation

Why it surfaced

Abstract-reviewed clinical cohort study scored conservatively for prevention; 7/10 reflects the available design, relevance, novelty, and population or unmet-need evidence.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.